Synta (SNTA) Management Ready to Take Company to Next Level; Roth Affirms 'Buy' Rating
Roth Capital affirms Synta Pharmaceuticals (Nasdaq: SNTA) at Buy with a $27 target price following recent meetings with management. Analyst Joseph Pantginis noted thay Synta management hinted that the company is well-positioned for business development progression, which may also include partnerships.
Yes, and the article points out that partnership(s) may be occurring soon. Potential partners are coming back around. Also, the article points out that the CEO selection process is moving along and an announcement of a new CEO could happen soon.